FDA Head Robert Califf Battles Misinformation — Sometimes With Fuzzy Facts
FDA Commissioner Robert Califf has called misinformation one of the deadliest killers in the United States. As the FDA tries to fight that scourge, it sometimes stumbles.
FDA
141 - 160 of 465 Results
-
-
Once the New Over-the-Counter Birth Control Pill Is Available, What About Cost and Coverage?
The Food and Drug Administration’s approval is viewed as groundbreaking, but many details still must be figured out.
The Long Road to Reining In Short-Term Plans
Episode 305President Biden made good on a campaign promise this week with a proposal that would limit short-term health insurance plans that boast low premiums but also few benefits. Meanwhile, the Supreme Court’s decision to outlaw affirmative action programs could set back efforts to diversify the nation’s medical workforce. Alice Miranda Ollstein of Politico, Amy Goldstein of the Washington Post, and Rachel Cohrs of Stat News join KFF Health News’ chief Washington correspondent Julie Rovner to discuss these issues and more. Also this week, Rovner interviews KFF Health News’ Bram Sable-Smith, who reported the latest KFF Health News-NPR “Bill of the Month” about how a hospital couldn’t track down a patient, but a debt collector could.
-
As Low-Nicotine Cigarettes Hit the Market, Anti-Smoking Groups Press for Wider Standard
The first FDA-authorized cigarettes with 95% less nicotine than traditional smokes will go on sale in California, Florida, and Texas starting in early July. Anti-smoking groups oppose greenlighting just one plant biotech’s products and instead urge federal regulators to set a low-nicotine standard for the entire industry.
By Don Thompson -
E-Cigs Are Still Flooding the US, Addicting Teens With Higher Nicotine Doses
The FDA, Justice Department, and White House have failed to act as vapes with kid-friendly flavors like cotton candy or gummy bears proliferate.
By Liz Szabo -
Drugmakers Are Abandoning Cheap Generics, and Now US Cancer Patients Can’t Get Meds
A quality-control crisis at an Indian pharmaceutical factory has left doctors and their patients with impossible choices as cheap, effective, generic cancer drugs go out of stock.
By Arthur Allen -
How the Mixed Messaging of Vaccine Skeptics Sows Seeds of Doubt
Some GOP members of the House Select Subcommittee on the Coronavirus Pandemic have two-stepped around vaccine skepticism, proclaiming themselves to be pro-vaccine while also validating the beliefs of people who oppose vaccine mandates. The result could have serious public health consequences.
By Darius Tahir -
Mood-Altering Mushroom Sales Bloom Despite Safety Concerns
The well-known “Amanita muscaria” mushroom is legal to possess and consume in 49 states. The market for gummies, powders, and capsules containing extracts of the fungus is raising eyebrows, though, amid concerns from the FDA and in the absence of human clinical trials.
-
Watch: 5th Circuit Judges Question Two-Decade-Old Approval of Abortion Pill
The 5th Circuit Court of Appeals in New Orleans heard oral arguments Wednesday in a case brought by conservative Christian abortion opponents seeking to revoke FDA approval of mifepristone, a medication used in more than half of abortions in the U.S.
By Sarah Varney The Crisis Is Officially Ending, but Covid Confusion Lives On
Episode 297The public health emergency declaration for covid-19 ends May 11, ushering in major changes in how Americans can access and pay for the vaccines, treatments, and tests particular to the culprit coronavirus. But not everyone will experience the same changes, creating a confusing patchwork of coverage — not unlike health coverage for other diseases. Meanwhile, outside advisers to the FDA formally recommended allowing a birth control pill to be sold without a prescription. If the FDA follows the recommendation, it would represent the first over-the-counter form of hormonal contraception. Margot Sanger-Katz of The New York Times, Tami Luhby of CNN, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join KFF Health News’ Julie Rovner to discuss these issues and more. Plus for “extra credit” the panelists suggest health policy stories they read this week they think you should read, too.
-
Legal Pot Is More Potent Than Ever — And Still Largely Unregulated
As marijuana has become far more mainstream, potent, and sometimes dangerous, uneven regulation at the state and federal levels leaves consumers at risk.
-
Federal Rules Don’t Require Period Product Ingredients on Packaging Labels. States Are Stepping In.
New York and California have passed laws requiring disclosure of ingredients on menstrual product packaging. Advocates want more transparency across the U.S.
By Erica Zurek -
Listen: Mifepristone Remains Available for Now. What Happens Next?
The Supreme Court on April 21 ruled that the abortion pill mifepristone should remain widely available while the lower courts consider the issue, blocking earlier rulings that banned or restricted access to the drug. KFF Health News’ Julie Rovner joined NPR’s “Weekend All Things Considered” to discuss the complicated case.
-
Social Media Is Fueling Enthusiasm for New Weight Loss Drugs. Are Regulators Watching?
Online platforms are overflowing with testimonials for GLP-1s. The drugs show promise for inducing weight loss, but many aren’t FDA-approved for that use.
By Darius Tahir and Hannah Norman The Confusing Fate of the Abortion Pill
Episode 293The legality and availability of the abortion pill mifepristone is in question after a federal judge in Texas canceled the FDA’s approval of the first drug used in the two-drug medication abortion regimen. A 5th Circuit Court of Appeals panel overruled that decision in part, saying the pill should remain available, but only under the onerous restrictions in place before 2016. Meanwhile, another federal judge in Washington state issued a ruling in a separate case that conflicts with the Texas decision, ordering the FDA not to roll back any of its restrictions on the drug. Victoria Knight of Axios, Shefali Luthra of The 19th, and Sarah Karlin-Smith of the Pink Sheet join KFF Health News chief Washington correspondent Julie Rovner to discuss these issues and more.
-
Doctors’ Lesson for Drug Industry: Abortion Wars Are Dangerous to Ignore
The American Medical Association ducked the abortion issue for years and now sees its members’ professional opinions second-guessed by lawmakers and judges. PhRMA is following the same playbook.
By Julie Rovner -
FDA Evaluates ‘Safety Concerns’ Over Dental Devices Featured in KHN-CBS Investigation
A KHN and CBS News investigation found that a dental appliance called the AGGA has been used by more than 10,000 patients, and multiple lawsuits allege it has caused grievous harm to patients.
A Judicial Body Blow to the ACA
Episode 291A federal judge in Texas has dealt a big setback to the Affordable Care Act. The same judge who tried in 2018 to declare the entire ACA unconstitutional has now ruled that the law’s main provisions for preventive care are unconstitutional and, therefore, unenforceable nationwide. Also this week, North Carolina became the 40th state to expand Medicaid under the ACA. Alice Miranda Ollstein of Politico, Rachel Cohrs of Stat, and Sandhya Raman of CQ Roll Call join KHN chief Washington correspondent Julie Rovner to discuss these issues and more.
-
Judge Signals He Could Rule to Halt Sales of Common Abortion Pill
A U.S. District Court case is being widely followed because the judge’s decision could overturn the FDA’s approval of mifepristone two decades ago. With abortion rights polling well even in red states, anti-abortion activists are increasingly turning to the courts to achieve their aims.
By Sarah Varney -
FDA Looks Into Dental Device After KHN-CBS News Investigation of Patient Harm
The FDA’s interest in the AGGA dental device follows a KHN-CBS News investigation, according to a former agency official.